News | May 27, 2026
Novo Nordisk study exposes “hidden” inflammation driving cardio risk despite care
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
The new facility marks Align’s first manufacturing presence in India and its fourth globally
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
Subscribe To Our Newsletter & Stay Updated
